Neurogene stockholders approve directors, executive pay at 2026 Annual Meeting

Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

• low

  Stockholders elected Robert Baffi and Rohan Palekar as Class III directors for three-year terms through 2029, with both receiving strong support (94% and 99% approval respectively).

  Item 5.07 verify on EDGAR →
• low

  Executive compensation approved on advisory basis with 99% support, indicating shareholder satisfaction with management pay practices.

  Item 5.07 verify on EDGAR →
• low

  Deloitte & Touche LLP ratified as 2026 auditor, though 17% of votes cast were against the appointment—a notable minority dissent for an auditor vote.

  Item 5.07 verify on EDGAR →